TipRanks
Advertisement
Advertisement
Foghorn Therapeutics downgraded to Neutral from Buy at BTIG
PremiumThe FlyFoghorn Therapeutics downgraded to Neutral from Buy at BTIG
2d ago
Foghorn Therapeutics downgraded at Citizens after FHD-909 discontinuation
Premium
The Fly
Foghorn Therapeutics downgraded at Citizens after FHD-909 discontinuation
3d ago
Foghorn Therapeutics downgraded to Market Perform from Outperform at Citizens
Premium
The Fly
Foghorn Therapeutics downgraded to Market Perform from Outperform at Citizens
3d ago
Foghorn Therapeutics Announces Major Strategic Reprioritization, Layoffs
PremiumCompany AnnouncementsFoghorn Therapeutics Announces Major Strategic Reprioritization, Layoffs
3d ago
Foghorn, Lilly to not advance FHD-909 program, Foghorn to reduce workforce
Premium
The Fly
Foghorn, Lilly to not advance FHD-909 program, Foghorn to reduce workforce
3d ago
Foghorn Therapeutics Reports Q2 Results and Pipeline Progress
Premium
Company Announcements
Foghorn Therapeutics Reports Q2 Results and Pipeline Progress
2M ago
Foghorn Therapeutics: AACR 2026 Data De‑Risk Pipeline and Expand Commercial Opportunity, Supporting Buy Rating and $13 Target
PremiumRatingsFoghorn Therapeutics: AACR 2026 Data De‑Risk Pipeline and Expand Commercial Opportunity, Supporting Buy Rating and $13 Target
5M ago
Foghorn Therapeutics presents new preclinical data for FHD-909
Premium
The Fly
Foghorn Therapeutics presents new preclinical data for FHD-909
6M ago
Foghorn Highlights Preclinical Chromatin Oncology Advances at AACR
Premium
Company Announcements
Foghorn Highlights Preclinical Chromatin Oncology Advances at AACR
6M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―